COMMUNIQUÉS West-GlobeNewswire

PetVivo Sets Fiscal Third Quarter 2026 Conference Call for Monday, February 16, 2026 at 5:00 p.m. ET
09/02/2026
MINNEAPOLIS, MN, US, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering [...]
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
09/02/2026
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business [...]
SafeSpace Global Corp. (OTCID: SSGC) Announces Investor Day to be held in Nashville, Tennessee on February 27, 2026
09/02/2026
Company to Meet with Investors and Financial Institutions During Event Knoxville, TN, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC) ("SafeSpace" or the "Company"), a provider of [...]
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
09/02/2026
SCOTTSDALE, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2025 [...]
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
09/02/2026
Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “ [...]
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
09/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL [...]
AB Science annonce que la Food and Drug Administration (FDA) américaine a accordé le statut de Minor Use in Major Species (MUMS) au Masivet® dans le traitement des tumeurs mastocytaires chez le chien
09/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE QUE LA FDA A ACCORDÉ LE STATUT DE “MINOR USE IN MAJOR SPECIES” (MUMS) AU MASIVET DANS LE TRAITEMENT DES TUMEURS MASTOCYTAIRES CHEZ LE CHIEN AB SCIENCE PRÉSENTE LES PERSPECTIVES DE [...]
Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/02/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/02/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Synfini Introduces Integrated Microscale Purification, Delivering Assay-Ready Compounds in Hours Instead of Days
09/02/2026
New Capability Collapses the Design-Make-Test-Analyze (DMTA) Cycle, Accelerating Real SAR Learning with High-purity Compounds for Direct-to-Biology Screening MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Synfini [...]
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
09/02/2026
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company [...]
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
09/02/2026
Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- [...]
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
09/02/2026
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic [...]
Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
09/02/2026
SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its fourth quarter and full year 2025 results on Thursday [...]
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
09/02/2026
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “ [...]
QuantX Biosciences Closes Oversubscribed $85M Series B Financing
09/02/2026
Round co-led by LAV and Sanofi Ventures PRINCETON, N.J. and SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- QuantX Biosciences, Inc. , a computationally driven drug discovery and development company using advanced modeling [...]
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
09/02/2026
Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
09/02/2026
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for [...]
Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping
09/02/2026
SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium [...]

Pages